NCT01883804View on ClinicalTrials.gov

Effect of Methyldopa on MHC Class II Antigen Presentation in Type 1 Diabetes

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions
Diabetes Mellitus, Type 1
Interventions
DRUG

Methyldopa

6 weeks of Methyldopa administration; where the dose will be increased according to safety of efficacy.

Trial Locations (1)

80045

Barbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora

Sponsors
All Listed Sponsors
collaborator

Juvenile Diabetes Research Foundation

OTHER

lead

University of Colorado, Denver

OTHER